Citations

Institution: Mayo Clinic Clear

Showing 10 of 108119 citations.

Risk of Post-Polypectomy Bleeding After Colorectal Endoscopic Mucosal Resection in Patients with Chronic Kidney Disease: A Propensity-Matched Analysis of the US Collaborative Network
Patel, Feenalie N. , Ramai, Daryl , Sr, Khaled, Shaik, Danial H., Thakkar, Shyam , Rex, Douglas K. , Beran, Azizullah , Elfert, Khaled , Mohamed, Mouhand , Canakis, Andrew , Sr, Khaled, Bhavsar‐Burke, Indira , Guardiola, John J.

No container title available | April 25, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-6398416/v1 Get It

Abstract Background Studies evaluating the risk of post-polypectomy bleeding (PPB) after colorectal endoscopic mucosal resection (EMR) in patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD) are limited. Methods This retrospective cohort study utilized the U.S. Collaborative Network to assess the risk of PPB after colorectal EMR in patients with CKD compared to controls. Using one-to-one propensity score matching (PSM), the primary outcome measured was PPB within 30 days after colorectal EMR. The PPB risk was further stratified by CKD severity: non-advanced CKD and advanced CKD. Results After PSM, each cohort included 7,460 patients. Overall, CKD was associated with increased risk of PPB following colorectal EMR (5.5% vs. 4%, odds ratio [OR] 1.38, 95% confidence interval [CI] 1.19–1.61, p < 0.001). The PPB risk was significantly higher in patients with advanced CKD (8.1% vs, 4.6%, OR 1.83, 95% CI 1.43–2.34, p < 0.001), while those with non-advanced CKD showed modest increase in risk of PPB (4.7% vs. 3.9%, OR 1.21, 95% CI 1.001–1.46, p = 0.049). Conclusion Patients with CKD had higher risk of PPB than patients without CKD, but absolute risk remained low. The PPB risk was notably increased in patients with advanced CKD. Optimizing patients with CKD, especially advanced CKD, before colorectal EMR and monitoring for post-procedure bleeding remains important.
2024 Alzheimer's Association criteria for Alzheimer's disease diagnosis are usually anchored to both plaques and tangles, not Aβ alone
Jack, Clifford R. , Knopman, David S., Wiste, Heather J. , Jagust, William J. , Murray, Melissa E., Boon, Baayla D.C. , Lowe, Val J. , Graff‐Radford, Jon, Petersen, Ronald , Murray, Melissa E. , Jack, Clifford R , Murray, Melissa E , Sperling, Reisa Anne , Johnson, Derek R. , Burkett, Brian J. , Cogswell, Petrice M. , Graff‐Radford, Jonathan , Vemuri, Prashanthi

Alzheimer's & Dementia | April 25, 2025 | Volume: 21 | Issue: 4 | Pages: No page available

10.1002/alz.70184 | PMID 40276985 Get It

Twenty Years Later, “AL Amyloidoma” Not “Non‐Mutated ApoA1”: Enhanced Diagnosis Through Mass Spectrometry Advancement
Zhang, Tony , Dingli, David , Murry, David L., Mills, John R. , Pinto, Marcus Vinícius , Pinto, Marcus V , Klein, Christopher J , Dingli, David , Klein, Christopher J.

Muscle & Nerve | April 25, 2025 | Volume: 72 | Issue: 1 | Pages: 168-171

10.1002/mus.28415 | PMID 40275648 Get It

Complex Metabolomic Changes in a Combined Defect of Glycosylation and Oxidative Phosphorylation in a Patient with Pathogenic Variants in PGM1 and NDUFA13
Radenkovic, Silvia , Adant, Isabelle , Bird, Matthew , Swinnen, Johannes V. , Cassiman, David , Ghesquière, Bart , Bird, Matthew J , Gruenert, Sarah C , Ghesquière, Bart , Kozicz, Tamás , Morava, Éva

Cells | April 25, 2025 | Volume: 14 | Issue: 9 | Pages: 638

10.3390/cells14090638 | PMID 40358162 Get It

Inherited metabolic disorders (IMDs) are genetic disorders that occur in as many as 1:2500 births worldwide. Nevertheless, they are quite rare individually and even more rare is the co-occurrence of two IMDs in one individual. To better understand the metabolic cross-talk between glycosylation changes and deficient energy metabolism, and its potential effect on outcomes, we evaluated patient fibroblasts with likely pathogenic variants in PGM1 and pathogenic variants in NDUFA13 derived from a patient who passed away at 16 years of age. The patient presented with characteristic of PGM1-CDG including bifid uvula, muscle involvement, abnormal glycosylation in blood, and elevated liver transaminases. In addition, hearing loss, seizures, elevated plasma and CSF lactate and a Leigh-like MRI brain pattern were present, which are commonly associated with Leigh syndrome. PGM1-CDG has been reported in about 70 individuals, while NDUFA13 deficiency has so far only been reported in 13 patients. As abundant energy is essential for glycosylation, and both PGM1 and NDUFA13 are linked to energy metabolism, we sought to better understand the underlying biochemical cause of the patient’s clinical presentation. To do so, we performed extensive investigations including tracer metabolomics, lipidomics and enzymatic studies on the patient’s fibroblasts. We found a profound depletion of UDP-hexoses, consistent with PGM1-CDG. Complex I enzyme activity and mitochondrial function were also impaired, corroborating complex I deficiency and Leigh syndrome. Further, lipidomics analysis showed similarities with both PGM1-CDG and OXPHOS-deficient patients. Based on our results, the patient was diagnosed with both PGM1-CDG and Leigh syndrome. In summary, we present the first case of combined CDG and Leigh syndrome, caused by (likely) pathogenic variants in PGM1 and NDUFA13, and underline the importance of considering the synergistic effects of multiple disease-causing variants in patients with complex clinical presentation, leading to the patient’s early demise.
Asynchronous Technical Feedback: A Workshop for Training Surgical Instructors
Brian, Riley , Fernández, Úrsula Figueroa , Lund, Sarah , Cruz, Enrique , Navarro, Sergio M. , Varas, Julián , Navarro, Sergio Michael , Gomes, Camilla , Silvestri, Caitlin J. , Jarry, Cristián , O’Sullivan, Patricia

MedEdPORTAL | April 25, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.15766/mep_2374-8265.11519 | PMID 40290420 Get It

Abstract CT186: EVEREST-2: A seamless phase 1/2 study of A2B694, a logic-gated Tmod CAR T-cell therapy, in patients with mesothelin-expressing solid tumors with human leukocyte antigen-A*02 loss of heterozygosity
Molina, Julian R. , Dorigo, Oliver , Avila, Monica , Konecny, Gottfried E. , Ward, Jeffrey D. , Block, Matthew S. , Specht, Jennifer M. , Lou, Yanyan, Xuan, Jacqueline D., Eskander, Ramez N. , Ong, Gayanie, Langeberg, Wendy, Mardiros, Armen, Maloney, David G. , Welch, John S. , Hecht, J. Randolph, Specht, Jennifer , Hazim, Antonious , Punekar, Salman R. , Simeone, Diane M. , Kirtane, Kedar , Ward, Jeffrey, Boyd, Leslie R. , Park, Jong Chul , Xuan, Jacqueline D., Davila, Marco L , Maus, Marcela V , Locke, Frederick L. , Wise, Andrea

Cancer Research | April 25, 2025 | Volume: 85 | Issue: 8_Supplement_2 | Pages: CT186-CT186

10.1158/1538-7445.am2025-ct186 Get It

Abstract Background: Chimeric antigen receptor T-cell (CAR T) therapies have demonstrated significant clinical efficacy in hematologic malignancies, but have proven challenging in solid tumors, in part owing to a lack of tumor-specific targets and unmanageable toxicity. Mesothelin (MSLN) expression normally is limited to the mesothelium of major body cavities but can be upregulated in diverse solid tumor types (cancer.gov/tcga), making it a potential target for cancer therapy. MSLN-targeted cell therapy approaches, including CAR T and T-cell receptor fusion therapies, have shown promising clinical activity; however, on-target, off-tumor toxicity including fatal events have occurred (Beatty, et al. Gastroenterology. 2018.; Haas, et al. Mol Ther. 2023.; Hong, et al. ESMO 2021. Abstract 9590.). A2B694 is an autologous logic-gated, MSLN-targeted Tmod CAR T therapy that addresses the challenges of on-target, off-tumor toxicity by combining 2 CARs: an activating and blocking receptor. The activator recognizes MSLN present on the surface of both tumor and normal cells; the blocker inhibits the CAR T activator when it binds human leukocyte antigen (HLA)-A*02, which is present in normal cells and often lost in tumor cells. Thus, in patients with tumor-associated HLA-A*02 loss of heterozygosity (LOH), the blocker prevents on-target, off-tumor toxicity on normal cells owing to retained HLA-A*02 expression (Hamburger, et al. Mol Immunol. 2020). Through this unique selective mechanism, A2B694 may provide a therapeutic window to treat patients with MSLN-expressing solid tumors exhibiting HLA-A*02 LOH. Methods: EVEREST-2 (NCT06051695) is a first-in-human, phase 1/2, open-label, nonrandomized study to evaluate the safety and efficacy of A2B694 in adults with recurrent unresectable, locally advanced, or metastatic cancers with MSLN expression, including non-small cell lung cancer, colorectal cancer, pancreatic cancer, ovarian cancer, mesothelioma, or other solid tumors with MSLN expression. Eligible patients must have progressed following standard of care therapy. Enrollment to EVEREST-2 occurs through the prescreening study BASECAMP-1 (NCT04981119), which identifies patients with tumor-associated HLA-A*02 LOH via next-generation sequencing (Tempus AI, Inc). Eligible patients enroll in the BASECAMP-1 study and undergo leukapheresis. A2B694 is manufactured from cryopreserved T cells when clinically appropriate for patients. The primary objective of phase 1 is to evaluate the safety and tolerability of A2B694 and identify the recommended phase 2 dose (RP2D). The dose-expansion phase will confirm RP2D and collect biomarker data to further characterize A2B694. Phase 2 will assess overall response rate per RECIST v1.1. The first patient was enrolled on EVEREST-2 in April 2024. Dose escalation is ongoing. Citation Format: Julian R. Molina, Antonious Hazim, Oliver Dorigo, Salman R. Punekar, Monica Avila, Diane M. Simeone, Kedar Kirtane, Gottfried E. Konecny, Jeffrey Ward, Matthew Block, Jennifer Specht, Leslie Boyd, Yanyan Lou, Jong Chul Park, Jacqueline D. Xuan, Ramez N. Eskander, Gayanie Ong, Marco Davila, Wendy Langeberg, Marcela Maus, Armen Mardiros, Frederick L. Locke, Andrea Wise, David G. Maloney, John Welch, J. Randolph Hecht. EVEREST-2: A seamless phase 1/2 study of A2B694, a logic-gated Tmod CAR T-cell therapy, in patients with mesothelin-expressing solid tumors with human leukocyte antigen-A*02 loss of heterozygosity [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_2):Abstract nr CT186.
Dilated Cardiomyopathy Evaluation with Imagenomics: Combining Multimodal Cardiovascular Imaging and Genetics
Galanti, Kristian , Dabbagh, Ghaith Sharaf , Ricci, Fabrizio , Gallina, Sabina, Giansante, Roberta , Jacob, Ron , Obeng‐Gyimah, Edmond, Prasad, Sanjay , Birnie, David H. , Landstrom, Andrew P. , Mohammed, Selma F. , Landstrom, Andrew P , Mohammed, Selma , Mohiddin, Saidi , Khanji, Mohammed Yunus , Chahal, Choudhary Anwar A , Sharaf Dabbagh, Ghaith , Ricci, Fabrizio , Gallina, Sabina , Jacob, Ron, Cooper, Leslie T. , Prasad, Sanjay K , Khanji, Mohammed Y , Chahal, C. Anwar A.

ESC Heart Failure | April 25, 2025 | Volume: 12 | Issue: 4 | Pages: 2669-2690

10.1002/ehf2.15307 | PMID 40275589 Get It

Abstract Dilated cardiomyopathy (DCM) is a clinical diagnosis characterized by the presence of left ventricular dilatation and systolic dysfunction unexplained by abnormal loading conditions or coronary artery disease. However, a broad range of phenotypic manifestations, encompassing isolated scar, DCM with preserved ejection fraction, and overt DCM, should be regarded as a diagnostic classification representing a broad spectrum of underlying aetiologies, including both inherited and acquired heart muscle disorders. A multimodal non-invasive imaging approach is essential for accurate morpho-functional assessment of cardiac chambers and is key to establish the cardiac phenotype and to rule out an underlying ischaemic aetiology. Furthermore, advanced imaging techniques enable deep cardiovascular phenotyping and non-invasive tissue characterization. The aim of this review is to propose a systematic approach to the diagnosis of DCM, emphasizing the importance of genetics and clinical findings for a precise and practical clinical approach. Also, we strive to qualify the role of cardiac imaging in the diagnosis of DCM, particularly on the relevance of novel techniques and clinical utility of actionable parameters to improve current diagnostic schemes and risk stratification algorithms. We further elaborate on the role of cardiac imaging to deliver optimal guidance to aetiology-based therapeutic approaches, verification of treatment response and disease progression monitoring.
Pediatric Pituitary Adenomas and Cysts: A 46-Year Population-Based Analysis
Leopold, Kaitlin , Salama, Mostafa , Kumar, Seema , Creo, Ana L. , Nofal, Alaa Al , Lteif, Aida, Creo, Ana , Salama, Mostafa , Al Nofal, Alaa , Tapia, Amanda L.

Journal of the Endocrine Society | April 24, 2025 | Volume: 9 | Issue: 6 | Pages: No page available

10.1210/jendso/bvaf069 | PMID 40321172 Get It

Abstract Context Pituitary adenomas and cysts are rare in pediatric patients and improved understanding can guide management recommendations. Objective To report incidence, presentation, management, and outcomes in a pediatric population-based cohort with pituitary adenomas and cysts, and to explore the relationship between these lesions and brain magnetic resonance imaging (MRI) rates, as well as lesion size and headaches with disease progression. Methods In this retrospective cohort study of pediatric patients (≤18 years) with incident pituitary adenomas and cysts in Olmsted County, MN, from 1976 to 2021, 234 unique patients were identified using diagnostic codes through the Rochester Epidemiology Project, with 37 confirmed cases of pituitary adenoma or cyst included. Incidence rates were calculated using census data. Descriptive statistics were used for extracted clinical data. Results Incidence of pediatric adenomas and cysts was 2.29 cases per 100 000 person-years. Of the 37 cases, 68% were nonfunctioning adenomas or cysts, 27% were prolactinomas, and there was 1 each of growth hormone (GH)– and thyrotropin (TSH)-secreting adenomas. Median lesion diameter was 5.5 mm (IQR, 4.0-8.0). Median follow-up was 7.4 years (IQR, 4.5-15.4). Four patients had disease progression which stabilized with second-line therapy. Brain MRI rates did not correlate with lesion incidence. No clinically meaningful relationship was found between lesion size or headache and disease progression. Conclusion Pituitary adenomas and cysts are rare in pediatric patients. Most are small, nonfunctioning, and stable on long-term follow-up. Larger studies on small nonfunctioning pituitary lesions are needed to enhance understanding of their natural history and develop long-term management recommendations.
Reconstruction of Clival Defects using Vascularized Free and Pedicled Flaps: Systematic Review and Proposed Algorithms
Kumar, Nitish , Marino, Michael J. , Miglani, Amar , Gomes, Pedro Lança , Kumar, Nitish , Chang, Brent A. , Marks, Lisa , Lal, Devyani

Journal of Neurological Surgery Part B: Skull Base | April 24, 2025 | Volume: 87 | Issue: 02 | Pages: 165-172

10.1055/a-2576-7289 | PMID 41808964 Get It

Abstract Reconstruction of clival defects may be challenging in expanded endonasal skull base surgery. We conducted a systematic review to evaluate the outcomes of vascularized flaps used for clival reconstruction. The following databases were searched using a combination of Medical Subject Headings (MeSH) and keywords related to clival reconstruction in July 2024: Ovid Medline, Ovid Embase, Scopus, and Web of Science. Studies reporting outcomes of clival reconstruction with vascularized free and pedicled flaps in patients were selected for complete review. Twenty-three studies were included for detailed study. Clival reconstruction with free flaps was done in 18 patients; 17 had a successful repair, outcome was not reported for 1. Facial vessels were preferred for microvascular anastomosis. Radial artery forearm flap and anterolateral thigh flap were most utilized. Pedicled flaps were used in 68 patients, with reported success in 85.3%. Nasoseptal flap was the most common intranasal flap, used in 34 patients with successful reconstruction in 85.3%. Temporoparietal fascia flap was the most common extranasal flap, successfully used in 13 patients. Intranasal pedicled flaps, wherever available, were preferably used for primary reconstruction; extranasal flaps were the next choice. Free flaps were reserved for salvage reconstruction due to prior failed or unavailable local pedicled flaps. Satisfactory reconstructive outcomes are reported using pedicled and free flaps. The flap of choice is determined by the previous surgical history, radiotherapy, wound vascularity, defect size, overall health of the surrounding nasal mucosa, simultaneous clival surgery, and the preferred pedicle transposition route (free flaps).
Global Barriers to Otolaryngology Care
Patterson, Rolvix H. , Bangash, Ali Haider , Pandey, Akansha, Elwell, Zachary , Adeyemo, Adebolajo A. , Cahill, Gabrielle , Cherches, Alexander , Daudu, Davina , Der, Carolina , Din, Taseer , Hapunda, Racheal , Ibekwe, Titus , Maina, Ivy W. , Mukuzi, Allan, Nakku, Doreen , Petrucci, Beatriz, Pietrobon, Carolina, Salano, Valerie , Sprow, Holly N. , Waterworth, Christopher J. , Wiedermann, Joshua P. , Xu, Mary Jue , Alkire, Blake C., Okerosi, Samuel , Initiative, Global Otolaryngology–Head and Neck Surgery, Bhutta, Mahmood F. , Dillard, Lauren K. , Ncogoza, Isaie , Lin, H.C., Potent, Keith, Adel, Iman, Wiedermann, Joshua , Cherches, Alexander D , Din, Taseer , Ncogoza, Isaie , Bangash, Ali Haider , Patterson, Rolvix H , Zalaquett, Nader , Pandey, Akansha, Nuss, Sarah , Fei‐Zhang, David J. , Srinivasan, Tarika , Fagan, Johannes J. , Kahinga, Aveline Aloyce , Seguya, Amina , Shaye, David , Smith, Emily R. , Tamir, Sharon Ovnat , Wen, Christopher Z. , Initiative, Global Otolaryngology–Head and Neck Surgery, Shah, Keshav V. , Potent, Keith

JAMA Otolaryngology–Head & Neck Surgery | April 24, 2025 | Volume: 151 | Issue: 6 | Pages: 604

10.1001/jamaoto.2025.0573 | PMID 40272811 Get It

ImportanceUnderstanding the global barriers to otolaryngology–head and neck surgery (OHNS) care is crucial in addressing disparities in access to care, particularly in low-income and middle-income countries (LMICs).ObjectiveTo characterize barriers to comprehensive otolaryngology care across World Bank income groups.Design, Setting, and ParticipantsUsing an online cross-sectional survey that was administered by the Global OHNS Initiative via international and national professional societies, personal contacts, and social media, this study captured the perceptions of otolaryngologists regarding barriers to OHNS care at the levels of the country, health sector, clinician, and patient. Participants included otolaryngologists from the 194 World Health Organization member states and Taiwan. Eligibility criteria included a medical degree and specialized training in managing conditions of the ear, nose, and throat. The nonresponse rate was not recorded. The data collection period spanned from October 2022 to June 2023.ExposuresExposures included World Bank income group classification.Main Outcomes and MeasuresThe primary outcomes were Likert scale responses regarding frequency of barriers to OHNS care. The a priori hypothesis was that LMICs would report more frequent barriers to OHNS care.ResultsThe study involved 146 otolaryngologists (47 female individuals [32%]), with 69 (47%) from high-income countries and 77 (53%) from LMICs. Male individuals represented 45 high-income country respondents (65%) and 54 LMIC respondents (70%). Barriers were reported across income groups at all levels of the health system, with a higher frequency in LMICs. Several barriers were reported to be more substantial in LMICs, such as the national volume and distribution of otolaryngologists, financial compensation for clinicians, and patient stigma, and others were common across income settings, such as the availability of operating rooms and inflexible working hours. Common concerns included national and health sector barriers: OHNS workforce, referral networks, government support; clinician barriers: excessive clinician workloads, understaffing, poor administration support; patient barriers: distance to health care facilities, financial burdens such as medical costs and foregone wages, stigma, and health literacy.Conclusions and RelevanceThe results of this cross-sectional study suggest that there are barriers to otolaryngology care globally that affected all levels of the health care system. This work may inform prioritization of otolaryngology within research and policy, and it emphasizes the need for effective strategies to expand access to otolaryngology care, particularly in lower-income settings.